Mergers and acquisitions have had a “devastating” effect on research and development efforts at drug companies over the next decade, according to John L. LaMattina, who ran Pfizer’s R&D laboratories from 2003 until 2007. This could lead to fewer new drugs being invented at a time when “our understanding of the basis of diseases continues to increase substantially,” LaMattina writes in a scientific article published today.
